Children’s Healthcare of Atlanta and Emory University Lead National Trial Aiming to Improve Bleeding and Survival in Extremely Preterm Infants
ATLANTA (July 24, 2025) – Children’s Healthcare of Atlanta and Emory University are leading a national multi-site trial to determine the best threshold for platelet transfusions in extremely preterm infants admitted to the Neonatal Intensive Care Unit (NICU) at Arthur M. Blank Hospital. These babies generally have the highest incidence of abnormally low platelets in the blood and bleeding, as well as the highest mortality among all babies admitted to the NICU. Led by Ravi Patel, MD, MSc, Director of Neonatal Clinical Research and Neonatologist for Children’s, the goal of the trial is to try to improve survival and outcomes for these tiny patients.
“The trial will test the hypothesis that among extremely preterm infants born at 23 to 26 weeks gestation, a low platelet transfusion threshold, compared to a high threshold, will improve survival without major or severe bleeding up to 40 weeks,” said Dr. Patel, principal investigator.
Infants born extremely preterm during these weeks have a higher risk of developing bleeding and not surviving compared to more mature infants. This is especially true in the first week after birth, a particularly high-risk period for bleeding. A platelet transfusion may decrease the risk of bleeding by helping clots form, but the correct threshold for giving these transfusions based on their platelet count, a routine test in the NICU, is not yet clearly understood by neonatal researchers. Once known, the hope is that giving the transfusion at the correct threshold will improve bleeding and potentially survival.
“We hope knowledge generated from the trial may improve outcomes in our most vulnerable patients,” said Dr. Patel, who is also a professor of Pediatrics at Emory University School of Medicine.
As Principal Investigator, Dr. Patel will oversee the seven-year, multi-site, randomized trial and lead the clinical coordinating center through NICUs at Children’s. Martha Sola-Visner, MD, director of the Newborn Medicine Clinical Research Program at Boston Children’s and professor in Pediatrics at Harvard Medical School, will serve as co-principal investigator of the clinical coordinating center. They aim to enroll more than 2,000 infants across all sites with about 100 from Children’s. Research Triangle Institute (RTI) International will serve as the data coordinating center.
The trial is funded by $8.7 million National Institutes of Health (NIH) grant and will be conducted at 15 NICUs across the country through the Neonatal Research Network, a consortium of NICUs with established site research infrastructure and extensive experience conducting multicenter clinical trials with early recruitment of these high-risk infants, as well as six additional centers in the U.S. The Neonatal Research Network is part of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
About Children's Healthcare of Atlanta
As the only freestanding pediatric healthcare system in Georgia, Children’s Healthcare of Atlanta is the trusted leader in caring for kids. The not-for-profit organization’s mission is to make kids better today and healthier tomorrow through more than 60 pediatric specialties and programs, top healthcare professionals, and leading research and technology. Children’s is one of the largest pediatric clinical care providers in the country, managing more than one million patient visits annually at three hospitals (Arthur M. Blank, Hughes Spalding and Scottish Rite), Marcus Autism Center, the Center for Advanced Pediatrics, the Zalik Behavioral and Mental Health Center, urgent care centers and neighborhood locations. Consistently ranked among the top children’s hospitals by U.S. News & World Report, Children’s Healthcare of Atlanta has impacted the lives of kids in Georgia, across the United States and around the world for more than 100 years thanks to generous support from the community.
About Emory University School of Medicine
Emory University School of Medicine is a leading institution with the highest standards in education, biomedical research and patient care, with a commitment to recruiting and developing a diverse group of students and innovative leaders. Emory School of Medicine has more than 3,400 full- and part-time faculty, 592 medical students, 497 allied health students in five programs, 1,388 residents and fellows in 115 accredited programs, and 92 MD/PhD students. Medical school faculty received $588.4 million in external research funding in fiscal year 2022. The school is best known for its research and treatment in infectious disease, brain health, heart disease, cancer, transplantation, orthopaedics, pediatrics, renal disease, ophthalmology and geriatrics.